TNF and rheumatoid arthritis: RA patients who received the single anti-TNF-α biologic treatment-Etanercept had more RA-related outpatient visits (means of pre-RA vs. post-RA: 19.9 vs. 21.9; p < 0.01), but shorter lengths of stay (1.3 vs. 1.1; p < 0.01) and fewer emergency room visits (0.8 vs. 0.5; p < 0.01).